CD81

CD81 antigen · P60033 · CD81 on Sugi Atlas →

1,146 patent compounds predicted against CD81, 374 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3081440	0.51	2/20
SCHEMBL12387135	0.51	2/20
SCHEMBL29388686	0.51	2/20
SCHEMBL867255	0.49	2/20
SCHEMBL3374503	0.49	2/20
SCHEMBL30478474	0.45	2/20
Menthiafolic Acid (SCHEMBL1812045)	0.38	2/20
Menthiafolic Acid (SCHEMBL1812046)	0.38	2/20
Menthiafolic Acid (SCHEMBL28864402)	0.38	2/20
SCHEMBL9652696	0.36	2/20
SCHEMBL1224393	0.36	2/20
Hydrochloric Acid (SCHEMBL28230474)	0.35	2/20
SCHEMBL15164226	0.34	2/20
Echinocystic Acid (SCHEMBL42864)	1.00	1/20
Echinocystic Acid (SCHEMBL741321)	1.00	1/20
Echinocystic Acid (SCHEMBL741322)	1.00	1/20
Echinocystic Acid (SCHEMBL4454760)	1.00	1/20
Echinocystic Acid (SCHEMBL13629642)	1.00	1/20
Echinocystic Acid (SCHEMBL17030511)	1.00	1/20
Echinocystic Acid (SCHEMBL17131708)	1.00	1/20

Clinical trials — most relevant to CD81 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa	PHASE2/PHASE3	UNKNOWN
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis	PHASE3	COMPLETED
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection	PHASE1/PHASE2	COMPLETED
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma	PHASE2	COMPLETED
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC	PHASE2	ACTIVE_NOT_RECRUITING
Dose Escalation Study of Immunomodulatory Nanoparticles	PHASE1	ACTIVE_NOT_RECRUITING
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc	PHASE1	COMPLETED
Assessing the Immunogenicity of pING-hHER3FL	PHASE1	ACTIVE_NOT_RECRUITING
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults	PHASE1	COMPLETED
Immune and Viral Outcomes of HIV-1 Therapy Interruption	PHASE1	COMPLETED
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation	PHASE1	RECRUITING
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma	PHASE1	ACTIVE_NOT_RECRUITING
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck	PHASE1	WITHDRAWN
The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma	PHASE1	RECRUITING
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms	EARLY_PHASE1	COMPLETED
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms	EARLY_PHASE1	UNKNOWN
Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia	nan	NOT_YET_RECRUITING
Extracellular Vesicle Surface Markers In Acute Cerebrovascular Syndromes.	nan	UNKNOWN
Identification of New Diagnostic Protein Markers for Colorectal Cancer	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients	nan	RECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease	nan	NOT_YET_RECRUITING
Precision Physical Exercise for Personalized Onco-Hematology.	nan	NOT_YET_RECRUITING
JAK2V617F Mutated Endothelium Has a Stem Cell Potential in Primary Myelofibrosis: a New Disease Ontogenesis for Chronic Myeloproliferative Disorders	nan	COMPLETED
Alterations in CD8αβ and CD8αα T Cell Levels in Patients With Rheumatoid Arthritis	nan	UNKNOWN
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients	nan	COMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Children and Adult Hemophagocytic Syndrome (HLHa)	nan	COMPLETED
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD81 binder may also engage these)

Protein	Name	Similarity
P60034	—	1.000	P60034 →
O97703	—	1.000	O97703 →
P35762	—	1.000	P35762 →
Q9N0J9	—	1.000	Q9N0J9 →
Q62745	—	1.000	Q62745 →
Q3ZCD0	—	1.000	Q3ZCD0 →
Q8R3G9	—	0.993	Q8R3G9 →
P19075	—	0.992	P19075 →
Q2KIS9	—	0.989	Q2KIS9 →
O60635	—	0.987	O60635 →
Q5R9S6	—	0.986	Q5R9S6 →
P41731	—	0.984	P41731 →
Q6AYR9	—	0.984	Q6AYR9 →
Q4R7W6	—	0.983	Q4R7W6 →
Q6NWG0	—	0.983	Q6NWG0 →
Q9XSK2	—	0.981	Q9XSK2 →
Q5RC27	—	0.981	Q5RC27 →
P28648	—	0.980	P28648 →
Q99J59	—	0.980	Q99J59 →
Q61451	—	0.979	Q61451 →
Q28709	—	0.978	Q28709 →
Q3T0S3	—	0.976	Q3T0S3 →
CD63	CD63 antigen	0.976	landscape →
P40237	—	0.975	P40237 →
P19397	—	0.975	P19397 →
Q58DM3	—	0.973	Q58DM3 →
Q76B49	—	0.973	Q76B49 →
O70352	—	0.973	O70352 →
P41732	—	0.971	P41732 →
Q7YQL0	—	0.970	Q7YQL0 →